This rebound is blocked by the combined addition of both a PI3Kalpha and a PI3Kbeta inhibitor; however, in PTEN-deficient mouse models of prostate cancer this efficient PI3K inhibition causes a marked activation of AR activity [254]. Here, PIK3CG is linked to prostate carcinoma.